Clinical studies at the Tübingen site

ARCA (Autosomal-Recessive Cerebellar Ataxias)

In this DZNE network research project (Autosomal Recessive Cerebellar Ataxia Registry, ARCA registry), modern methods are being used to search for new ataxia genes and biomarkers in autosomal recessive ataxias and early onset ataxias with onset before the age of 40.

DANCER (Establishment of a Recruitment Pool of Potential Study Participants, of Realtives and a Control Group for DZNE Studies)

One focus of these studies is the identification of early, specific changes, for example in the blood, so that the diagnosis of a neurodegenerative disease such as dementia or Parkinson's can be made at a very early stage. This enables a better understanding of the diseases and supports the development of new forms of therapy.

DANCER-FTD (Recruitment of Realtives and a Control Group for the DESCRIBE-FTD Study)

In order for us to assess study outcomes of patients with neurological frontotemporal dementia (FTD), comparative studies with relatives of patients with FTD as well as interested individuals without a diagnosis of neurodegenerative disease are needed.

DANCER-PSP (Recruitment of Realtives and a Control Group for the DESCRIBE-PSP Study)

Comparative studies with relatives of patients with PSP and interested individuals without a diagnosis of neurodegenerative disease are needed to assess study outcomes of patients with progressive supranuclear palsy (PSP).

DESCRIBE (DZNE - Clinical Register Study of neurodegenerative Disorders)

The aim of the DESCRIBE study is to use the examination results obtained in the course of normal patient care together with findings from diagnostics on biomaterials, including genetic analysis, for scientific purposes.

DESCRIBE-FTD (DZNE - Clinical Registry Study on Frontotemporal Dementia (FTD))

DESCRIBE-PSP (DZNE - Clinical Registry Study on Progressive Supranuclear Paresis (PSP))

DIAN (Longitudinal Study on Dominantly Inherited Alzheimer's Disease)

Hereditary Alzheimer's disease, caused by gene mutations, is extremely rare - but those who carry it inevitably develop dementia, usually even before the age of 60. The DIAN network wants to gain insights from this for the very common sporadic Alzheimer's dementia and future therapies.

ENABLE (Patient- and care-related benefits of amyloid PET imaging)

The aim of the ENABLE trial is to test whether amyloid PET screening has the potential to improve the care of dementia patients in the German health care system and thus contribute to the preservation or slowed loss of everyday functions.

ESMI (European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative)

The aim of this study is to assemble a trial-ready cohort of sufficient size consisting of patients with spinocerebellar ataxia type 3 (SCA 3) and first-degree relatives, so-called at-risk individuals, for future drug trials.

HSP-Net (Networking Project on Hereditary Spastic Paraplegia)

Spastic spinal paralysis (HSP) is a rare, often hereditary, slowly progressive disease characterized by a spastic gait disorder. The HSP project involves the establishment and conduct of a multicenter study of the natural longitudinal course of hereditary spastic spinal paralysis.

Prospect-AD (Population-based screening over speech for clinical trials in Alzheimer’s Disease)

Subjective memory impairment (SCD) or mild cognitive impairment (MCI) may be associated with an increased risk of dementia later in life. Early preventive measures can potentially reduce the risk of dementia. This requires early detection of early signs of cognitive impairment.

SCA Registry (Registry for Spinocerebellar Ataxies (SCA))

The goals of the SCA Registry are to characterize the natural history of the disease, identify prognostic factors, and develop novel imaging and biochemical biomarkers. By including at-risk individuals, we place a special focus on studying the preclinical disease phase.

SPORTAX-NHS (Observational Study on Adult Onset Sporadic Ataxias)

The SPORTAX study aims to precisely characterize the two forms of the disease and to compare the courses of the disease. In addition, factors are to be identified that allow a more precise assignment of the disease at an early stage and that can influence the development of the disease.